Radar · Genomics in California
Best Genomics Companies in California, United States
The 803 best Genomics companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: 23andMe.
By Riya SenguptaFinancials
803companies tracked
$26.9Bdisclosed funding
6unicorns
495have raised
FLIAR INTELLIGENCE · GENOMICS × CALIFORNIA
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
84%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
736kcombined LinkedIn audience
54%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Genomics companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | 23andMe 🦄 Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | $861M | 31 mo ago | 755 755 → 549 (-27%) · sector median +32% | Anne Wojcicki Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+37 | 200 patents Consumer genomics: DNA testing, ancestry analysis, and secure genetic data processing. | — |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | — | — |
| 3 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | WordPressBugHerdApple iCloud Mail+25 | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 4 | Human Longevity Provider of precision medicine, preventative health assessments, and longevity care | $409M | 21 mo ago | 85 | J Venter Co-Founder & CEO | TurbopackNode.jsYouTube+23 | 71 patents AI-driven multi‑omic analytics for disease risk assessment, diagnosis, and genomic trait prediction | 1 launch · 1 partnership |
| 5 | BillionToOne 🦄 Provider of cell-free cancer liquid biopsy test | $389M | 23 mo ago | 47 | Oguzhan Atay Co-Founder & CEO | WordPress Block EditorWordPressSentry+20 | 50 patents cfDNA methylation quantification and sequencing assay quality control for diagnostics | 1 launch · 1 partnership · 1 award |
| 6 | Maze Therapeutics Developer of genetic bio-markers in neurological, metabolic, and renal diseases 53Funding top 22%News top 24%Growth top 31%Moat top 46% All 9 signals ▾Fundingtop 22% Newstop 24% Growthtop 31% Moattop 46% Marketbottom 49% Techbottom 49% Fin. healthbottom 44% Talentbottom 40% Globalbottom 39% Funding: Raised $381M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 23 tracked, 5 types) · +125% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $381M | 9 mo ago | 111 111 → 155 (+40%) · sector median +32% | Jason Coloma CEO | WordPressApple iCloud MailMicrosoft 365+16 | — | — |
| 7 | Karius Provider of diagnostics for identifying infectious diseases using microbial DNA | $315M | 25 mo ago | 139 139 → 212 (+53%) · sector median +32% | Tim Blauwkamp Chief Scientific Officer | Cart FunctionalitySanitySentry+33 | 81 patents Rapid metagenomic sequencing workflows for pathogen detection and microbial biomarker analysis. | — |
| 8 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | 94 | Damien Mcdevitt President | WordPress Block EditorWordPressMySQL+19 | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 9 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 21 mo ago | 54 54 → 75 (+39%) · sector median +32% | Jonathan Romanowsky Co-Founder and Chief Business Officer | WordPressMySQLPHP+24 | 52 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 10 | Genome Medical Provider of clinical and DTC genomic testing services | $173M | 21 mo ago | 84 84 → 74 (-12%) · sector median +32% | — | WordPressApple iCloud MailGoogle Workspace+30 | — | — |
| 11 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | — | — |
| 12 | Atlas Data Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent… 29Funding top 26%Moat top 40%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 26% Moattop 40% Talentbottom 49% Techbottom 45% Marketbottom 35% Globalbottom 33% Funding: Raised $155M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $155M | 13 mo ago | — | Varun Mehta CEO | WordPress Block EditorWordPressMySQL+19 | — | — |
| 13 | Clear Labs Provider of food safety technologies for the identification of pathogens 60Patents top 19%Funding top 22%Innovation top 28%Moat top 28% All 10 signals ▾Patentstop 19% Fundingtop 22% Innovationtop 28% Moattop 28% Growthtop 32% Talenttop 41% Globalbottom 44% Marketbottom 40% Techbottom 33% Newsbottom 21% Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $141M | 18 mo ago | 55 55 → 85 (+55%) · sector median +32% | Sasan Amini Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+16 | 79 patents Automated liquid handling and cartridge systems for nucleic‑acid sequencing sample preparation | — |
| 14 | Mission Bio Provider of single cell multiomics platform for genotypic and phenotypic analysis 82Funding top 18%Tech top 21%Innovation top 25%Product top 25% All 10 signals ▾Fundingtop 18% Techtop 21% Innovationtop 25% Producttop 25% Talenttop 28% Moattop 31% Growthtop 37% Markettop 44% Globalbottom 39% Newsbottom 27% Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 10 mo ago | 109 109 → 89 (-18%) · sector median +32% | Adam Sciambi Co-Founder & Chief Technology Officer | SanityTurbopackSentry+34 | — | 1 launch · 1 partnership |
| 15 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Manish Agarwal Co-Founder | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 16 | Addition Therapeutics Developer of RNA-mediated genetic medicines 42Funding top 22%Talent top 38%Moat top 42%Market bottom 40% All 5 signals ▾Fundingtop 22% Talenttop 38% Moattop 42% Marketbottom 40% Globalbottom 36% Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $106M | 6 mo ago | — | Kathleen Collins Founder | — | — | — |
| 17 | Antheia Genetically engineered yeast cells to produce medicinal products 64Funding top 20%Patents top 25%Moat top 28%Innovation top 34% All 12 signals ▾Fundingtop 20% Patentstop 25% Moattop 28% Innovationtop 34% Producttop 35% Growthtop 36% Talenttop 40% Techtop 45% Newstop 45% Partnerstop 45% Globalbottom 47% Marketbottom 45% Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $96M | 4 mo ago | 50 50 → 66 (+32%) · sector median +32% | Christina Smolke Co-Founder & CEO | WordPressMySQLPHP+28 | 82 patents Biotechnological production and optimization of opioid alkaloids (benzylisoquinoline and morphinan) | 2 job openings |
| 18 | ChromaCode Digital molecular biology analytics for disease management | $91M | 16 mo ago | 46 | — | — | 42 patents Multiplexed digital PCR for nucleic acid and cfDNA analysis in diagnostics | — |
| 19 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 11 mo ago | 35 35 → 41 (+17%) · sector median +32% | Mads Melbye Co-Founder | WebflowReactTypekit+21 | 49 patents Non‑invasive prenatal diagnostics via methylation and RNA biomarkers for pregnancy monitoring | — |
| 20 | Personalis Provider of genomic sequencing and diagnosis software for the healthcare industry | $87M | 17 mo ago | 310 310 → 402 (+30%) · sector median +32% | Atul B Co-founder and Scientific Advisor | WordPressMySQLMariaDB+22 | 83 patents Clinical genomics data analysis pipelines for cancer, mosaicism, methylation and multi-species NGS | — |
| 21 | Prolific Machines Provider of photomolecular biology platform to control cellular functions | $86M | 22 mo ago | 30 | Declan Jones Co-Founder & CIO | SanityApple iCloud MailGoogle Workspace+11 | 14 patents Optogenetic platforms for scalable stem cell culture and directed cell differentiation | — |
| 22 | Ansa Biotechnologies Provider of DNA synthesis technology using enzymes 74Growth top 26%Funding top 27%Patents top 27%Moat top 32% All 11 signals ▾Growthtop 26% Fundingtop 27% Patentstop 27% Moattop 32% Innovationtop 33% Newstop 38% Producttop 40% Markettop 41% Techtop 43% Talenttop 45% Globalbottom 47% Growth: Headcount 159 → 253 (+59%) across vintages · Fresh capital in last 24 mo Funding: Raised $82.0M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $82M | 8 mo ago | 253 | Sebastian Palluk Co-Founder & CTO | WordPress Block EditorWordPressApple iCloud Mail+27 | 32 patents Enzymatic nucleic acid synthesis and polymerase engineering for synthetic biology applications | 1 job opening · 1 award |
| 23 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Dave Mullarkey Chief Executive Officer | — | — | — |
| 24 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | Lei Qi Founder | WordPressMySQLPHP+21 | — | — |
| 25 | Genedit Developer of drug delivery system for genetic medicines 53Funding top 28%Talent top 28%Product top 30%Patents top 31% All 9 signals ▾Fundingtop 28% Talenttop 28% Producttop 30% Patentstop 31% Innovationtop 34% Moattop 36% Marketbottom 41% Techbottom 40% Globalbottom 40% Funding: Raised $58.5M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $58M | 18 mo ago | 39 39 → 64 (+64%) · sector median +32% | — | — | 73 patents Non‑viral cationic polymers for biomolecule delivery and engineered Cpf1 guide RNAs | — |
| 26 | Cartography Biosciences Provider of a platform to discover immunotherapeutics 24Funding top 23%Moat top 31%News top 39%Talent bottom 49% All 6 signals ▾Fundingtop 23% Moattop 31% Newstop 39% Talentbottom 49% Globalbottom 37% Marketbottom 27% Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $57M | 1 mo ago | 10 | Howard Chang Co-Founder | — | — | — |
| 27 | Actio Biosciences Developer of genetics-led therapies targeting shared biology between rare, common diseases | $55M | 12 mo ago | 21 | David Goldstein Co-Founder & CEO | WordPress Block EditorWordPressMySQL+9 | — | 1 job opening |
| 28 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | 29 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | 1 partnership |
| 29 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | 25 25 → 31 (+24%) · sector median +32% | Irene Yuan Co-Founder & Executive Vice President | — | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 30 | PeproMene Bio Developer of T-cell therapeutics for cancer treatment | $44M | 17 mo ago | 6 | — | WordPressMySQLPHP+15 | — | — |
| 31 | Electronic Bio Provider of nanotech-based DNA sequencing solutions 10Funding top 37%Talent bottom 45%Global bottom 29%Market bottom 24% All 5 signals ▾Fundingtop 37% Talentbottom 45% Globalbottom 29% Marketbottom 24% Techbottom 15% Funding: Raised $40.7M across 49 rounds · 49 rounds over 19 yrs (2.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $41M | 12 mo ago | 15 | Eric Ervin President and CEO | — | — | — |
| 32 | Xcell Biosciences Developer of cell culture analysis device for cancer research | $40M | 18 mo ago | 11 11 → 17 (+55%) · sector median +32% | — | WixSentryBootstrap+17 | 30 patents Advanced cell culture bioreactors for tumor microenvironment phenotypic modulation | — |
| 33 | JUMPCODE Genomics Provider of a technology for depleting unwanted nucleic acid | $39M | 15 mo ago | 27 | — | WordPressZohoSalesforce+18 | 57 patents Targeted NGS library preparation, enrichment, and transcriptome analysis technologies | — |
| 34 | Mercator MedSystems Developer of catheter-guided microfluid injection systems | $32M | 15 mo ago | 19 | Kirk Seward Founder | — | 105 patents Localized perivascular drug delivery devices for vascular disease treatment and prevention | — |
| 35 | Affinity Biosensors Developer of rapid antimicrobial susceptibility testing devices for life sciences 27Funding top 27%Moat top 31%Talent bottom 49%Patents bottom 46% All 7 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Patentsbottom 46% Innovationbottom 39% Globalbottom 36% Marketbottom 34% Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $31M | 2 mo ago | 21 | Ken Babcock CEO | — | 12 patents Rapid antimicrobial susceptibility testing via resonant mass and microchannel sensor technologies | — |
| 36 | Zafrens Provider of single-cell multi-omics analysis platform for researchers | $29M | 16 mo ago | 19 19 → 30 (+58%) · sector median +32% | Yi Zhang Co-Founder & EVP of Engineering | — | 6 patents Patents concentrated in computing, sensing & instrumentation | — |
| 37 | TriLink BioTech Developer of nucleic acid and mRNA products for research applications | $29M | 15 mo ago | 348 | — | Cart FunctionalityMagentoApple iCloud Mail+38 | — | 3 launchs · 1 expansion · 1 award |
| 38 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 6 mo ago | 9 | Jarret Glasscock Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 39 | Biolog Provider of cell-based phenotyping technologies and assays | $18M | 16 mo ago | 27 | — | WordPress Block EditorWordPressMySQL+25 | 27 patents Veterinary biologics for viral antigens and toxin neutralization, plus cell metabolic profiling diagnostics. | — |
| 40 | CrossLife Technologies Innovating molecular diagnostics for better health and saving lives | $16M | 11 mo ago | 6 | HyunDae Cho Founder & CEO | — | — | — |
| 41 | OncoCyte Developer of non-invasive diagnostic tests solutions for the treatment of cancer | $15M | 16 mo ago | 76 | Ron Andrews CEO & President | — | 40 patents Patents concentrated in chemistry & materials | — |
| 42 | Rejuvenation Technologies Developer of nucleoside-modified TERT mRNA for antiaging | $15M | 13 mo ago | 12 | Glenn Markov Co-Founder | — | — | — |
| 43 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — |
| 44 | Eclipse Bio Developer of cell-free immunoassay | $14M | 7 mo ago | 14 | Eric Van Nostrand Co-Founder | WordPressMySQLMariaDB+25 | — | 1 award |
| 45 | Osel Provider of microbiotics for women's health and GI diseases | $9M | 12 mo ago | 10 | Peter Lee Founder and Chairman | WordPressMySQLPHP+10 | 32 patents Vaginal probiotic formulations and bacteriocidal agents for female reproductive health | — |
| 46 | Simulations Plus Developer of modeling and simulation software and consulting services provider 62News top 24%Product top 24%Funding top 28%Fin. health top 33% All 11 signals ▾Newstop 24% Producttop 24% Fundingtop 28% Fin. healthtop 33% Growthtop 37% AItop 45% Techtop 48% Moattop 49% Innovationbottom 48% Marketbottom 47% Globalbottom 37% News: 19 BI events in 12 mo (of 179 tracked, 10 types) · +111% YoY Product: 1 product launch event in 12 mo · 6 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $8M | 11 mo ago | 197 197 → 197 (+0%) · sector median +32% | — | WordPressApple iCloud MailMicrosoft 365+26 | — | 1 job opening · 1 launch · 1 partnership |
| 47 | Arima Genomics Developer of technologies for genome sequence and structure | $7M | 11 mo ago | 48 | — | WordPressMySQLPHP+31 | 29 patents Patents concentrated in chemistry & materials | 1 partnership · 1 award |
| 48 | Nexilico Developer of computational tools for microbiome analytics | $3M | 9 mo ago | 4 | Mohammad Soheilypour CEO | — | — | — |
| 49 | MyoGene Bio Manufacturer of devices for muscular dystrophy treatment 8Talent top 38%Funding top 45%Global bottom 29%Market bottom 10% All 4 signals ▾Talenttop 38% Fundingtop 45% Globalbottom 29% Marketbottom 10% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $3.2M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 8/100 | $3M | 7 mo ago | 3 | April Pyle Co-Founder | — | — | — |
| 50 | LeafWorks Provider of DNA-based services for plant and fungal species identification 42Growth top 35%Tech top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Techtop 37% Moattop 38% Talenttop 38% Patentstop 43% Innovationtop 47% Fundingbottom 46% Globalbottom 33% Marketbottom 24% Growth: Fresh capital in last 24 mo Tech: 35 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 42/100 | $1M | 3 mo ago | 17 | Kerin Law Co-Founder & CSO | Cart FunctionalityShopifyBugHerd+32 | 8 patents Cannabis breeding: genetic testing, trait analysis, and sex‑control technologies | 3 partnerships |
Top 12 Genomics companies in California
#1
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#2
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 37.4% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#3
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#4
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#5
Series B · Foster City, California · founded 2020 · 10 employees$57Mraised▾
Series B · Foster City, California · founded 2020 · 10 employees
Provider of a platform to discover immunotherapeutics. It provides a platform that combines computational and experimental techniques to profile antigens of cancerous cells and identify targets for immuno-oncology treatments.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 23%Moat
top 31%News
top 39%Talent
bottom 49%Global
bottom 37%Market
bottom 27%Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- May 2026Series B—
- Oct 2025Series B$67M
- Jul 2022Series A$57M
Founders & team
Investors
8VC, Dren Bio, Hexagon, Myeloid Therapeutics, Alloy Therapeutics, Andreessen Horowitz
#6
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#7
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Series C · San Diego, California · founded 2018 · 94 employees
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 17%Patents
top 23%Moat
top 28%Innovation
top 33%Growth
top 35%News
top 45%Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Series C (Nov 2025)
Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 57 patents · Soonicorn
Audience (LinkedIn): 13k LinkedIn followers
Funding rounds
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
Founders & team
Investors
Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy
#8
Series C · Palo Alto, California · founded 2013 · 50 employees$96.4Mraised▾
Series C · Palo Alto, California · founded 2013 · 50 employees
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Moat
top 28%Innovation
top 34%Product
top 35%Growth
top 36%Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Series C (Jan 2026)
Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 82 patents · Soonicorn
Audience (LinkedIn): 10k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Associate Director of Global Quality, Senior Quality Control Manager
Funding rounds
- Jan 2026Series C$24M
- Jun 2025Series C$56M
- Jul 2024Series B$6M
- Jun 2022Venture Debt$40M
Founders & team
Investors
Viking Global Investors, Sherpalo Ventures, In-Q-Tel, Echo, Oxford Finance, SVB
Tech stack
BabelCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor
#9
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#10
Public · Redwood City, California · founded 2018 · 111 employees$381Mraised▾
Public · Redwood City, California · founded 2018 · 111 employees
Maze Therapeutics is involved in developing genetic biomarkers. The company is developing technologies in an integrated manner to identify genetic modifiers. It mainly focuses on genetic modifiers in neurological, metabolic and renal diseases, as well as oncology.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 22%News
top 24%Growth
top 31%Moat
top 46%Market
bottom 49%Tech
bottom 49%Funding: Raised $381M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Post IPO (Sep 2025)
News: 9 BI events in 12 mo (of 23 tracked, 5 types) · +125% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Headcount 77 → 111 (+44%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 28k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Sep 2025Post IPO$150M
- Dec 2024Series D$115M
- Jan 2022Series C$190M
- Oct 2019Series C—
Founders & team
Investors
Third Rock Ventures, Arch Venture Partners, Google Ventures, Foresite Capital, Casdin Capital, Alexandria Venture Investments
Tech stack
Amazon Web ServicesApple Icloud MailDocusignGoogle AnalyticsHttp/3Jquery
#11
Series B · Santa Barbara, California · founded 2006 · 21 employees$31.3Mraised▾
Series B · Santa Barbara, California · founded 2006 · 21 employees
Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Patents
bottom 46%Innovation
bottom 39%Global
bottom 36%Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Mar 2026Post IPO$2.3M
- Nov 2024Series B$14.4M
- Jun 2024Series A$3.7M
- Nov 2023Series A$2.4M
Founders & team
Investors
National Science Foundation
#12
Series A · San Francisco, California · founded 2021$106.5Mraised▾
Series A · San Francisco, California · founded 2021
Developer of RNA-mediated genetic medicines. The company uses PRINT technology to develop RNA-only therapeutics to transform genetic medicine.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 22%Talent
top 38%Moat
top 42%Market
bottom 40%Global
bottom 36%Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Alliance for mRNA Medicines (AMM)) announced in 12 mo
Funding rounds
- Dec 2025Series A$106.5M
Founders & team
Investors
SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, Gates, BEVC
Funding & investor landscape
$26.9Btotal disclosed funding
484companies funded
1,917disclosed rounds
5rounds last 90 days
Most active investors
Notable founders
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Dave Mullarkey
Chief Executive Officer · ClearNote Health
Howard Chang
Co-Founder · Cartography Biosciences
Ansuman Satpathy
Co-Founder · Cartography Biosciences
Yang Li
Co-Founder · ReviR Therapeutics
Damien Mcdevitt
President · Aspen Neuroscience
Christina Smolke
Co-Founder & CEO · Antheia
Prism market signals · United States · country-scoped Prism corpus, 1,273,702 docs
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Bioinformatics in California is moving
A read on the academic research around Bioinformatics in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,143 papers.
UC San Francisco, Berkeley, and San Diego lead California's 1,143 bioinformatics papers, dominated by genomics and single-cell transcriptomics research, with an optimistic tone (548 breakthroughs vs. 157 concerns).
1143 papers · stance +0.52 · 57% breakthrough · 16% concern
top institutions
- University of California, San Francisco182
- University of California, Berkeley153
- University of California San Diego150
- University of California, Los Angeles135
- University of California, Davis107
leading researchers
Darren J. Obbard · Pankaj Dhakad · Dhobasheni Newman · Anushya Muruganujan · Jennifer A. Doudna · Anastasiya Moiseyenko
prism intelligence · tone & topics
92% positive · 2% critical tone
BiotechnologyMedical ResearchHealthPharmaceuticalsBiologyGenetics
▲
Breakthroughs548 · 48%
▲ 39%→49% share
▲1.3× share momentum0 median citations81% since 2021mostly methods-led
Transcriptome breakthroughs surged 2→44 papers, signaling rapidly intensifying multi-omics discovery in California bioinformatics research.
rising sub-themes (early→recent)
- Gene11→80
- Genome23→65
- Transcriptome2→44
- Immune system1→17
- Phenotype1→16
Newly emergingWorkflow 0→21 · Gene expression 0→20 · Disease 0→16
Landmark SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing · 26,554 cites
◆
Advancements252 · 22%
22%→22% share
▲1.0× share momentum0 median citations81% since 2021mostly empirical
Disease advancements rose 5→27 papers, reflecting sustained translational momentum linking genomic findings to clinical applications.
rising sub-themes (early→recent)
- Transcriptome1→23
- Disease5→27
- Immune system1→14
- Cancer1→13
- Gene3→14
Newly emergingGene expression 0→12 · Immunotherapy 0→9 · Biomarker 0→8
Landmark Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin · 5,843 cites
▼
Concerns157 · 14%
▼ 16%→14% share
▼0.9× share momentum0 median citations78% since 2021mostly reviews
Disease concerns jumped 1→21 papers, suggesting growing scrutiny over reliability and generalizability of bioinformatics disease models.
rising sub-themes (early→recent)
- Disease1→21
- Genome1→9
- Phenotype1→6
- Drug discovery1→5
- Epigenetics1→5
Newly emergingGene 0→12 · Biomarker 0→9 · Immune system 0→7
Landmark GENCODE: The reference human genome annotation for The ENCODE Project · 5,001 cites
Common questions
How many Genomics companies are there in California, United States?
Radar tracks 803 indexable Genomics companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Genomics companies in California, United States?
The Genomics companies in California, United States on this list have raised a combined $26.9B in disclosed equity funding across 484 funded companies.
Which is the highest-funded Genomics company in California, United States?
23andMe is the highest-funded Genomics company in California, United States, with $861M in disclosed equity funding.
How many Genomics companies in California, United States are funded?
484 of the 803 Genomics companies in California, United States on this list have disclosed at least one equity funding round.
How many Genomics unicorns are there in California, United States?
6 Genomics companies in California, United States on this list are valued at $1B or more.
Who are the top investors in California, United States Genomics companies?
The most active investors in California, United States Genomics companies on this list include HHS, Y Combinator, National Science Foundation, JLABS, Foresite Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.